Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA 2443950 C · Owner: Scott, William J. · Inventors: Wood, Jill E.; Scott, William J.; Sibley, Robert N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a group of quinolyl isoquinolyl and pyridyl ureas, their , use in treating raf mediated diseases and pharmaceutical compositions which contain these ureas for use in such therapy. These compounds have one of the following formulae:, A D B (I) , A'-D-B' (II) A"~D~B" (III) , wherein D is -NH-C (O)-NH-; A is a substituted pyridyl group; A' is an optionally, substituted isoquinolinyl group or a quinolinyl group; A" is a substituted quinolinyl , group, B and B' are each, independently a substituted or unsubstituted , bridged cyclic structure of up to 30 carbon atoms; and a cyclic moiety having at least 5 , members and B" is a substituted or unsubstituted up to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 18, 2002 and granted October 18, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.